SCHEDULE: FMR LLC Discloses 11% Stake in Alnylam Pharmaceuticals

FMR LLC, through its affiliates, has reported beneficial ownership of 11.0% of Alnylam Pharmaceuticals' common stock as of March 31, 2026.

Summary

• FMR LLC and its affiliates, including Abigail P. Johnson, have filed a Schedule 13G indicating beneficial ownership of 14,640,524.87 shares of Alnylam Pharmaceuticals Inc. common stock.
• This holding represents 11.0% of the class of securities outstanding as of March 31, 2026.
• The filing is an amendment (Amendment No. 23) to a previous Schedule 13G.
• FMR LLC is identified as an investment adviser (IA) and a holding company.
• Abigail P. Johnson is identified as an individual investor (IN).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of an existing significant ownership stake and does not contain new operational or financial performance information.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that significant holdings by large investment firms like FMR LLC in biotechnology companies such as Alnylam Pharmaceuticals often reflect confidence in the company's pipeline and long-term growth prospects, particularly in the RNAi therapeutics space.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by FMR LLC may be viewed positively by existing shareholders, potentially indicating continued institutional support and confidence in Alnylam Pharmaceuticals.

Key Dates

Keywords

Alnylam Pharmaceuticals, FMR LLC, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Holding Company, Abigail P. Johnson